Evidence map›Paper›PMID 35748885›Full record

ArticleBlood advances2022

American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis for patients with COVID-19: March 2022 update on the use of anticoagulation in critically ill patients.

Adam Cuker, Eric K Tseng, Holger J Schünemann, Pantep Angchaisuksiri, Clifton Blair, Kathryn Dane, Maria T DeSancho, David Diuguid, Daniel O Griffin, Susan R Kahn and 29 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood advances, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed, 1 pooled it
8.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 1 synthesis or guideline pooled it, 42 citations in OpenAlex.

  1. Guideline
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Review
  8. COVID-19 therapeutics.Clinical microbiology reviews · 2024
    Review
  9. Review
  10. Review
  11. Article
  12. Article
  13. COVID-19 and cardiovascular disease in patients with chronic kidney disease.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2024
    Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

39 authors at 20 institutions in 10 countries.

Adam CukerDepartment of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.ORCID 0000-0002-3595-5697
Eric K TsengDivision of Hematology/Oncology; St. Michael's Hospital, University of Toronto, Toronto, ON, Canada.ORCID 0000-0003-2745-8057
Holger J SchünemannDepartment of Health Research Methods, Evidence, and Impact, Michael G. DeGroote Cochrane Canada and GRADE Centres, McMaster University, Hamilton, ON, Canada.ORCID 0000-0003-3211-8479
Pantep AngchaisuksiriDivision of Hematology, Department of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.
Clifton BlairUnion, NJ.
Kathryn DaneDepartment of Pharmacy, The Johns Hopkins Hospital, Baltimore, MD.
Maria T DeSanchoDivision of Hematology-Oncology, Department of Medicine, Weill Cornell Medicine, New York Presbyterian Hospital, New York, NY.
David DiuguidDivision of Hematology, and.
Daniel O GriffinDivision of Infectious Diseases, College of Physicians & Surgeons of Columbia University, New York, NY.ORCID 0000-0001-5853-6906
Susan R KahnDepartment of Medicine, McGill University, Montreal, QC, Canada.ORCID 0000-0002-5667-8916
Frederikus A KlokDepartment of Medicine-Thrombosis and Hemostasis, Leiden University Medical Center, Leiden, the Netherlands.ORCID 0000-0001-9961-0754
Alfred Ian LeeSection of Hematology, Yale School of Medicine, New Haven, CT.ORCID 0000-0002-5968-3948
Ignacio NeumannEscuela de Medicina, Facultad de Medicina y Ciencia, Universidad San Sebastian, Santiago, Chile.
Ashok PaiDivision of Hematology & Oncology, Kaiser Permanente, Oakland/Richmond, CA.
Marc RighiniDivision of Angiology and Hemostasis, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland.
Kristen M SanfilippoWashington University School of Medicine St. Louis, St. Louis, MO.ORCID 0000-0002-0433-7845
Deborah M SiegalDepartment of Medicine and the Ottawa Hospital Research Institute, University of Ottawa, Ottawa, ON, Canada.ORCID 0000-0003-3806-3245
Mike SkaraCottage Grove, MN.
Deirdra R TerrellDepartment of Biostatistics and Epidemiology, Hudson College of Public Health, University of Oklahoma Health Sciences Center, Oklahoma City, OK.ORCID 0000-0003-0794-5851
Kamshad TouriToronto, ON, Canada.
Elie A AklDepartment of Internal Medicine, American University of Beirut, Beirut, Lebanon.ORCID 0000-0002-3444-8618
Reyad Al JabiriUniversity of Jordan, Amman, Jordan.
Yazan Al JabiriLincoln Medical Center, Bronx, NY.
Mary BoulosDepartment of Health Research Methods, Evidence, and Impact, Michael G. DeGroote Cochrane Canada and GRADE Centres, McMaster University, Hamilton, ON, Canada.ORCID 0000-0001-5046-598X
Romina Brignardello-PetersenDepartment of Health Research Methods, Evidence, and Impact, Michael G. DeGroote Cochrane Canada and GRADE Centres, McMaster University, Hamilton, ON, Canada.ORCID 0000-0002-6010-9900
Rana CharideClinical Research Institute, American University of Beirut, Beirut, Lebanon.ORCID 0000-0001-5512-0091
Luis E Colunga-LozanoDepartment of Clinical Medicine, Health Science Center, Universidad de Guadalajara, Guadalajara, Jalisco, Mexico.ORCID 0000-0001-7737-4914
Karin DearnessLibrary Services, St. Joseph's Healthcare Hamilton, Hamilton, ON, Canada.ORCID 0000-0002-6854-0156
Andrea J DarziDepartment of Health Research Methods, Evidence, and Impact, Michael G. DeGroote Cochrane Canada and GRADE Centres, McMaster University, Hamilton, ON, Canada.ORCID 0000-0002-2498-1697
Samer G KaramDepartment of Health Research Methods, Evidence, and Impact, Michael G. DeGroote Cochrane Canada and GRADE Centres, McMaster University, Hamilton, ON, Canada.ORCID 0000-0002-5167-4246
Gian Paolo MorganoDepartment of Health Research Methods, Evidence, and Impact, Michael G. DeGroote Cochrane Canada and GRADE Centres, McMaster University, Hamilton, ON, Canada.ORCID 0000-0001-7577-7963
Rami Z MorsiDepartment of Neurology, University of Chicago, Chicago, IL; and.ORCID 0000-0003-2131-3711
Binu A PhilipDepartment of Health Research Methods, Evidence, and Impact, Michael G. DeGroote Cochrane Canada and GRADE Centres, McMaster University, Hamilton, ON, Canada.
Yetiani Roldan BenitezDepartment of Health Research Methods, Evidence, and Impact, Michael G. DeGroote Cochrane Canada and GRADE Centres, McMaster University, Hamilton, ON, Canada.
Adrienne StevensDepartment of Health Research Methods, Evidence, and Impact, Michael G. DeGroote Cochrane Canada and GRADE Centres, McMaster University, Hamilton, ON, Canada.ORCID 0000-0002-6257-4806
Karla SoloDepartment of Health Research Methods, Evidence, and Impact, Michael G. DeGroote Cochrane Canada and GRADE Centres, McMaster University, Hamilton, ON, Canada.ORCID 0000-0001-6134-9140
Wojtek WierciochDepartment of Health Research Methods, Evidence, and Impact, Michael G. DeGroote Cochrane Canada and GRADE Centres, McMaster University, Hamilton, ON, Canada.ORCID 0000-0001-6576-1650
Reem A MustafaDepartment of Health Research Methods, Evidence, and Impact, Michael G. DeGroote Cochrane Canada and GRADE Centres, McMaster University, Hamilton, ON, Canada.ORCID 0000-0002-2091-0875
Robby NieuwlaatDepartment of Health Research Methods, Evidence, and Impact, Michael G. DeGroote Cochrane Canada and GRADE Centres, McMaster University, Hamilton, ON, Canada.
Cochrane · CAAmerican University of Beirut · LBJohns Hopkins Hospital · USKaiser Permanente Oakland Medical Center · USLeiden University Medical Center · NLLincoln Medical Center · USMahidol University · THMcGill University · CANewYork–Presbyterian Hospital · USSan Sebastián University · CLSt. Joseph’s Healthcare Hamilton · CASt. Michael's Hospital · CAUnitedHealth Group (United States) · USUniversidad de Guadalajara · MXUniversity Hospital of Geneva · CHUniversity of Chicago · USUniversity of Freiburg · DEUniversity of Jordan · JOUniversity of Kansas Medical Center · USUniversity of Oklahoma Health Sciences Center · US

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
Life after Recovery in Adult Thrombotic Thrombocytopenic Purpura (TTP): Let's Hear It from the SurvivorsK01HL135466 · NHLBI · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI TERRELL, DEIRDRA R · 2017 to 2021
$687k
NCATS NIH HHS UL1 TR001863NHLBI NIH HHS K01 HL135466
6 · The paper itself

Abstract

backgroundCOVID-19-related critical illness is associated with an increased risk of venous thromboembolism (VTE).

objectiveThese evidence-based guidelines of the American Society of Hematology (ASH) are intended to support patients, clinicians, and other health care professionals in decisions about the use of anticoagulation for patients with COVID-19.

methodsASH formed a multidisciplinary guideline panel, including 3 patient representatives, and applied strategies to minimize potential bias from conflicts of interest. The McMaster University Grading of Recommendations Assessment, Development and Evaluation (GRADE) Centre supported the guideline development process, including performing systematic evidence reviews (up to January 2022). The panel prioritized clinical questions and outcomes according to their importance for clinicians and patients. The panel used the GRADE approach to assess evidence and make recommendations, which were subject to public comment. This is an update to guidelines published in February 2021 and May 2021 as part of the living phase of these guidelines.

resultsThe panel made 1 additional recommendation: a conditional recommendation for the use of prophylactic-intensity over therapeutic-intensity anticoagulation for patients with COVID-19-related critical illness who do not have suspected or confirmed VTE. The panel emphasized the need for an individualized assessment of thrombotic and bleeding risk.

conclusionsThis conditional recommendation was based on very low certainty in the evidence, underscoring the need for additional, high-quality, randomized controlled trials comparing different intensities of anticoagulation for patients with COVID-19-related critical illness.

Indexed as

COVID-19HematologyVenous ThromboembolismAnticoagulantsCritical IllnessHumansUnited StatesAnticoagulants

Identifiers

PMID35748885
PMCPMC9236618
OpenAlexW4283388812

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.